All‐cause mortality ( · adult patients after liver transplantation.
Prostaglandin showed no clear difference in all‐cause mortality ( compared with placebo or standard care (low certainty).
1 finding from 1 review
Serious adverse eventsc ( · adult patients after liver transplantation.
Prostaglandin showed no clear difference in serious adverse eventsc ( compared with placebo or standard care (low certainty).
1 finding from 1 review
Health‐related quality of life · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Liver retransplantation ( · adult patients after liver transplantation.
Prostaglandin showed no clear difference in liver retransplantation ( compared with placebo or standard care (low certainty).
1 finding from 1 review
Primary non‐function of the allograft · adult patients after liver transplantation.
Prostaglandin showed no clear difference in primary non‐function of the allograft (at up to 1 month) compared with placebo or standard care (low certainty).
1 finding from 1 review
Acute kidney failure requiring dialysis ( · adult patients after liver transplantation.
Prostaglandin may leads to lower acute kidney failure requiring dialysis ( compared with placebo or standard care (low certainty).
1 finding from 1 review
Adverse events considered non‐serious · adult patients after liver transplantation.
It is very uncertain whether prostaglandin changes adverse events considered non‐serious ( compared with placebo or standard care (very low certainty).
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Varenicline leads to higher smoking abstinence at longest compared with placebo or no medication (high certainty).
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Cytisine probably leads to higher smoking abstinence at longest compared with placebo or no medication (moderate certainty).
1 finding from 1 review
Incidence of retinopathy at 4 to 5 years · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Progression of retinopathy · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Combined incidence and progression of diabetic retinopathy by 5 years · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Incidence of PDR/CSME/VH by 5 years · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · type 1 or type 2 diabetics
It is very uncertain whether blood pressure intervention/intensive blood pressure intervention changes visual acuity (loss of 3 lines or more) by 5 years compared with placebo/standard blood pressure intervention (very low certainty).
1 finding from 1 review
Adverse events—all‐cause mortality · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Adverse events: hypotension · type 1 or type 2 diabetics
Blood pressure intervention/intensive blood pressure intervention may leads to higher adverse events—hypotension compared with placebo/standard blood pressure intervention (low certainty).
1 finding from 1 review
QoL · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Survival Log‐rank analysis Study enrolment to last date of · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Adverse events NRS (scale from 0 to 10; lower score = less toxicity) · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Mean daily rating of problem severity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review